{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:44:56Z","timestamp":1782567896202,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the neonatal outcomes of progestin-primed ovarian stimulation (PPOS) and flexible gonadotropin-releasing hormone (GnRH) antagonist protocols.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective propensity score\u2013matched (PSM) cohort study. Women who underwent their first frozen embryo transfer (FET) cycle with freezing of all embryos followed by PPOS or GnRH antagonist protocols between January 2016 and January 2022 were included. Patients using PPOS were matched with the patients using GnRH antagonist at a 1:1 ratio. The main focus of this study was the neonatal outcomes of singleton live births, including preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), macrosomia and large for gestational age (LGA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 1:1 PSM, a total of 457 PPOS and 457 GnRH antagonist protocols were included for analysis. The average starting dose of gonadotropin (275.1 \u00b1 68.1 vs. 249.3 \u00b1 71.3, P&amp;lt;0.01) and total dose of gonadotropin (2799.6 \u00b1 579.9 vs. 2634.4 \u00b1 729.1, P&amp;lt;0.01) were significantly higher in the PPOS protocol than in the GnRH antagonist protocol. The other baseline and cycle characteristics were comparable between the two protocols. The rates of PTB (P=0.14), LBW (P=0.11), SGA (P=0.31), macrosomia (P=0.11) and LGA (P=0.49) did not differ significantly between the two groups. A total of 4 patients in the PPOS group and 3 patients in the GnRH antagonist group qualified as having congenital malformations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>PPOS resulted in singleton neonatal outcomes similar to those of a GnRH antagonist protocol. The application of the PPOS protocol is a safe option for infertility patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1156620","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:18:23Z","timestamp":1686896303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of the neonatal outcomes of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols: a propensity score\u2013matched cohort study"],"prefix":"10.3389","volume":"14","author":[{"given":"Mingze","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingnan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1404371","article-title":"Monitoring health outcomes of assisted reproductive technology","volume":"371","author":"Kissin","year":"2014","journal-title":"New Engl J Med"},{"key":"B2","article-title":"Morbidity and mortality weekly report","volume-title":"Surveillance summaries","author":"Sunderam","year":"2017"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32708-2","article-title":"A lancet commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China","volume":"397","author":"Qiao","year":"2021","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010035","article-title":"The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization","volume":"346","author":"Hansen","year":"2002","journal-title":"New Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2005.03.086","article-title":"In vitro fertilization is associated with an increase in major birth defects","volume":"84","author":"Olson","year":"2005","journal-title":"Fertil Steril"},{"key":"B6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/bmj.37957.560278.EE","article-title":"Perinatal outcome of singletons and twins after assisted conception: a systematic review of controlled studies","volume":"328","author":"Helmerhorst","year":"2004","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dei419","article-title":"Perinatal outcome of 12,021 singleton and 3108 twin births after non-IVF-assisted reproduction: a cohort study","volume":"21","author":"Ombelet","year":"2006","journal-title":"Hum Reprod"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-3-524","article-title":"Evidence of differential control of FSH and LH secretion by gonadotropin-releasing hormone (GnRH) from the use of a GnRH antagonist","volume":"67","author":"Hall","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-70-2-328","article-title":"Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists","volume":"70","author":"Hall","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","article-title":"Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization","volume":"104","author":"Kuang","year":"2015","journal-title":"Fertil Steril"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s210228","article-title":"Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Design Dev Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038153","article-title":"Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial","volume":"10","author":"Wang","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-019-2055-x","article-title":"Flexible GnRH antagonist protocol versus progestin-primed ovarian stimulation (PPOS) protocol in patients with polycystic ovary syndrome: comparison of clinical outcomes and ovarian response","volume":"39","author":"Xiao","year":"2019","journal-title":"Curr Med Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dez034","article-title":"Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial","volume":"34","author":"Beguer\u00eda","year":"2019","journal-title":"Hum Reprod"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.705264","article-title":"Comparison of the cumulative live birth rates of progestin-primed ovarian stimulation and flexible GnRH antagonist protocols in patients with low prognosis","volume":"12","author":"Du","year":"2021","journal-title":"Front Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.708704","article-title":"Comparison of dydrogesterone and medroxyprogesterone in the progestin-primed ovarian stimulation protocol for patients with poor ovarian response","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.664072","article-title":"Comparison of pregnancy and neonatal outcomes of single frozen blastocyst transfer between letrozole-induction and HRT cycles in patients with abnormal ovulation","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","article-title":"The international glossary on infertility and fertility care, 2017","volume":"108","author":"Zegers-Hochschild","year":"2017","journal-title":"Fertil Steril"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104779","article-title":"Birth weight reference percentiles for Chinese","volume":"9","author":"Dai","year":"2014","journal-title":"PloS One"},{"key":"B20","volume-title":"International statistical classification of diseases and related health problems 10th revision","year":""},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/humupd\/dmaa040","article-title":"Progestins for pituitary suppression during ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses","volume":"27","author":"Ata","year":"2021","journal-title":"Hum Reprod Update"},{"key":"B22","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1038\/s41598-017-08472-2","article-title":"Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011906","article-title":"Comparison of neonatal outcomes and live-birth defects after progestin-primed ovarian stimulation versus conventional ovarian stimulation for in vitro fertilization: a large retrospective cohort study","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4537-z","article-title":"Neonatal outcomes and congenital malformations in children born after human menopausal gonadotropin and medroxyprogesterone acetate treatment cycles","volume":"296","author":"Zhang","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s263138","article-title":"Live-birth outcomes and congenital malformations after progestin-primed ovarian stimulation in maternal endometriosis","volume":"14","author":"Liang","year":"2020","journal-title":"Drug Design Dev Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14622","article-title":"The pregnancy outcome of progestin-primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial","volume":"124","author":"Dong","year":"2017","journal-title":"BJOG"},{"key":"B27","doi-asserted-by":"publisher","first-page":"Cd001750","DOI":"10.1002\/14651858.CD001750.pub4","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"Cd001750","DOI":"10.1002\/14651858.CD001750.pub3","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","author":"Al-Inany","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/17.8.2027","article-title":"Obstetrical and neonatal outcome after controlled ovarian stimulation for IVF using the GnRH antagonist ganirelix","volume":"17","author":"Boerrigter","year":"2002","journal-title":"Hum Reprod"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/16.8.1588","article-title":"Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report","volume":"16","author":"Olivennes","year":"2001","journal-title":"Hum Reprod"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq072","article-title":"Large Prospective, pregnancy and infant follow-up trial assures the health of 1000 fetuses conceived after treatment with the GnRH antagonist ganirelix during controlled ovarian stimulation","volume":"25","author":"Bonduelle","year":"2010","journal-title":"Hum Reprod"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1156620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:18:27Z","timestamp":1686896307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1156620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":31,"alternative-id":["10.3389\/fendo.2023.1156620"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1156620","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"article-number":"1156620"}}